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Abstract
Background. The ANSWER study aims to identify risk
factors leading to increased cardiovascular morbidity and
mortality in a Spanish incident haemodialysis population.
This paper summarizes the baseline characteristics of this
population.
Methods. A prospective, observational, one-cohort study,
including all consecutive incident haemodialysis patients
from 147 Spanish nephrology services, was conducted. Pa-
tients were enrolled between October 2003 and September
2004. Sociodemographic, clinical, laboratory and health
care characteristics were collected.
Results. Baseline characteristics are described for 2341 in-
cident haemodialysis patients [mean (SD) age 65.2 (14.5)
years, 63% males]. The main cause of renal failure was di-
abetic nephropathy (26%). The majority of patients (57%)
had a Karnofsky score of 80–100 and 27% were followed
up by a nephrologist for ≤6 months. In total, 86% of the
patientshadhypertension,43%haddyslipidaemiaand44%
had a history of cardiovascular disease. Initial vascular ac-
cess was obtained via a temporary catheter in 30% of pa-
tients, via a permanent catheter in 16% and via an arteri-
ovenous fistula in 54%. Albumin levels were <3.5 g/dl
in 43% of patients. Immediately prior to the onset of
haemodialysis, the mean (SD) glomerular filtration rate
(GFR) was 7.6 (2.8) ml/min/1.73 m2, and only 6.7% of the
patients were within the K/DOQI guidelines for all four
bone mineral markers. In addition, a high proportion of
patients had anaemia markers outside the EBPG guidelines
(haemoglobin<11g/dl,59%,ferritin<100or>500ng/ml,
41% and saturated transferrin <20 or >40%, 50%) despite
previous treatment with erythropoiesis-stimulating agents
in 41% of cases.
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factors among incident haemodialysis patients in Spain.
The poor control of hypertension, anaemia, malnutrition
and mineral metabolism and late referral to a nephrologist
indicatetheneedforimprovingthetherapeuticmanagement
of patients before the onset of haemodialysis.
Keywords: cardiovascular; haemodialysis; malnutrition;
risk factors; vascular access
Introduction
Haemodialysis has become an increasingly safe and well-
tolerated therapy for patients with end-stage renal disease
(ESRD). Nevertheless, life expectancy of dialysis patients
remains significantly shorter than that of the general pop-
ulation with similar demographics [1]. There is also a high
incidence of cardiovascular morbidity and mortality in this
population [2,3]. Large, prospective, observational stud-
ies, including the Dialysis Outcomes and Practice Patterns
Study (DOPPS) [4], and the United States Renal Data Sys-
tem Dialysis Morbidity and Mortality Wave 2 study [5,6]
have provided important insights into the characteristics
andlikelyprognosisofhaemodialysispatients.Anumberof
prospective epidemiological studies from several European
countries have also described the incident haemodialysis
population [7–15], which can help to assess the influence
of a multitude of risk factors on the increased mortality
among these patients. In this regard, the ANSWER study is
currently underway in a large incident haemodialysis pop-
ulation in Spain.
The primary objective of the ANSWER study is to de-
termine and quantify the risk factors influencing cardio-
vascular morbidity and mortality in incident haemodialysis
patientsinSpain.Inaddition,thestudyalsoaimstoprovide
information on the baseline characteristics of the incident
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haemodialysis population; in this paper, we report these
data and make comparisons with other incident and preva-
lent populations reported in the literature.
Subjects and methods
ANSWER is a multicentre, prospective, observational co-
hortstudyinincidenthaemodialysispatientsalloverSpain.
Most dialysis facilities from Spain (n = 235) were invited
to participate in the study, of which 147 (62.5%) centres
agreedtoparticipate.Thelocalethicscommitteesapproved
the study and all patients enrolled in the study provided in-
formed consent.
Patients
All incident haemodialysis patients (i.e. patients start-
ing chronic haemodialysis treatment, who had received
haemodialysis for ≤30 days) aged ≥18 years were eligi-
ble for inclusion in the study. Patients were excluded if they
had undergone renal replacement therapy previously, were
already receiving haemodialysis (≥30 days) or peritoneal
dialysis, or had received a kidney transplant.
Following initiation of the study at each site in October
2003, patients were consecutively enrolled as they started
haemodialysis treatment. Enrolment was stratified by re-
gion according to the incidence of haemodialysis in a refer-
ence population [16], in order to obtain a sample in which
all Spanish regions would be represented in the same pro-
portion as in the target population.
Patient assessments
Sociodemographic, clinical, laboratory (maximum 30 days
before start of haemodialysis) and health care (concomi-
tant drug therapy and haemodialysis characteristics) vari-
ables were recorded at baseline (within first 30 days of
haemodialysis) and assessed at regular intervals during the
study period, with all the study patients followed up for at
least 2 years.
Variables recorded at baseline included waist measure-
ment, smoking status (active smoker, non-smoker, ex-
smoker), alcohol consumption (grams of alcohol [17]),
employmentstatusandeducation.Theclinicalvariablesas-
sessed included history of renal failure and various comor-
bidities: diabetes, dyslipidaemia [cholesterol >220 mg/dl
or low-density cholesterol (LDL-C) >100 mg/dl or treat-
ment with statins], hypertension [systolic blood pressure
(SBP) ≥140 mmHg or diastolic blood pressure (DBP)
≥90 mmHg or treatment with antihypertensives], parathy-
roidectomy, malnutrition (physician’s subjective assess-
ment) and cardiovascular disease (heart failure, left ven-
tricular hypertrophy, cardiac arrhythmia, ischaemic heart
disease, cerebrovascular disease, peripheral vascular dis-
ease and any other diseases of the circulatory system). The
Charlson age-comorbidity index [18,19], performance sta-
tus[Karnofskyscore(KS)]andhealth-relatedqualityoflife
(QoL) assessed with the Medical Outcome Survey Short
Form 36 (SF-36) questionnaire [20], previously validated
for the Spanish population [21], were also recorded.
Parameters describing the patients’ initial haemodialysis
experience (first month after starting) were also obtained.
Dialysis intolerance was defined as hypotension recorded
at >50% of dialyses performed during the past month.
The urea reduction ratio (URR) and Kt/V were calculated
for each patient according to a standard formula (second-
generation Daugirdas formula for eKt/V [22]). Glomerular
filtrationrate(GFR)wasestimatedaccordingtotheMDRD
equation [23].
Bone mineral markers [intact parathyroid hormone
(iPTH),phosphorus,totalcalciumandcalcium–phosphorus
product (Ca × P)] were assessed according to the Kid-
ney Disease Outcomes Quality Initiative (K/DOQI) target
ranges [24]. Anaemia markers (haemoglobin, haematocrit,
ferritin and saturated transferrin) were assessed according
to the European Best Practice Guidelines (EBPG) [25].
Statistical analysis
Summary statistics were calculated for continuous and cat-
egorical endpoints. Differences between subgroups were
assessed using chi-square tests for categorical variables
and Student’s t-test or the Mann–Whitney U-test for con-
tinuous variables (according to normality). The Bonferroni
method[26]wasappliedforadjustingthesignificancelevel
in these analyses. Differences were considered significant
at P < 0.00022 (0.05/228). Differences between means and
odds ratios with respect to the reference subgroup, together
with their 95% confidence interval, are displayed only for




Sociodemographic characteristics and aetiology of kidney
disease
A total of 2406 incident patients undergoing dialysis were
enrolled from 147 hospital nephrology services and as-
sociated haemodialysis centres throughout Spain between
1October2003and30September2004.Sixty-fivepatients
wereexcludedfromanalysis,astheydidnotmeettheinclu-
sion criteria. The resulting sample, 2341 patients, accounts
for ∼58% of the total incident patients during the study
period (according to the 2003 and 2004 estimates of the in-
cidence of haemodialysis in Spain of the National Registry
[27,28]).
Table 1 summarizes the patient demographics and base-
line characteristics. Most patients were elderly (29% over
75 years), male (63%) and overweight [59% had body mass
index (BMI) >25 kg/m2]. The education level was low
(38% had no primary education). The most common rea-
son for renal failure was diabetic nephropathy (26%), and
27% of patients had been followed up by a nephrologist
for <6 months prior to the onset of haemodialysis (24%
in the subgroup with diabetic nephropathy and 26% in the
subgroup with vascular nephropathy). The prevalence of
hepatitis C virus positive patients was 5.4%.580 R. P´ erez-Garc´ ıa et al.
Table 1. Baseline sociodemographic, clinical and haemodialysis characteristics of the study population
Mean (SD) or N (%) Mean (SD) or N (%)
Mean age (years) (SD) (n = 2336) 65.2 (14.5) Hypertension (n = 2283) 1975 (86%)
18–44 258 (11%) Diagnosed <1 year beforea (n = 1174) 152 (13%)
45–64 663 (28%) Previous cardiovascular diseaseb (n = 2341) 1038 (44%)
65–74 744 (32%) Ischaemic CV Disease 701 (30%)
≥75 671 (29%) Ischaemic heart disease 355 (15%)
Gender (n = 2341) Peripheral vascular disease 272 (12%)
Male 1470 (63%) Cerebrovascular disease 263 (11%)
Race (n = 2323) Heart failure 401 (17%)
Europid 2275 (98%) Cardiac arrhythmia 248 (11%)
Other 48 (2%) Other diseases of the circulatory system 141 (6%)
Mean BMI (kg/m2) (SD) (n = 2050) 26.6 (5.3) Left ventricular hypertrophy (n = 2341) 374 (16%)
BMI <20 kg/m2 146 (7%) Dyslipidaemiac (n = 2261) 973 (43%)
20≤BMI<25 kg/m2 701 (34%) Diagnosed <1 year beforea (n = 514) 108 (21%)
25≤BMI<30 kg/m2 (overweight) 787 (39%) Diabetes mellitus (n = 2285) 823 (36%)
Diagnosed <1 year beforea (n = 466) 19 (4%)
BMI ≥30 kg/m2 (obesity) 416 (20%) Malnutrition (n = 2246) 251 (11%)
Mean WC in males (cm) (SD) (n = 424) 96.5 (17.2) Parathyroidectomy (n = 2266) 15 (0.7%)
Mean WC in females (cm) (SD) (n = 253) 93.6 (16.9) Solid or non-solid tumour (n = 1992) 223 (11%)
Abd.ob. males (WC ≥ 102 cm) 144 (34%) Median Karnofsky score, (P25–P75)d (n = 2160) 80 (60–80)
Abd.ob. females (WC ≥ 88 cm) 167 (66%) <50 68 (3%)
Reasons for renal failure (n = 2280) 50–70 861 (40%)
Diabetic nephropathy 596 (26%) 80–100 1231 (57%)
Reno-vascular and hypertensive renal
disease
383 (17%) Mean of Charlson score (SD)e (n = 2249) 6.2 (2.4)
Glomerulonephritis 260 (11%) 2–6 1223 (55%)
Polycystic kidney disease 166 (7%) 7–8 648 (29%)
Chronic pyelonephritis 140 (6%) ≥9 378 (16%)
Systemic 90 (4%) SF-36f (n = 847)
Hereditary 15 (1%) Mean PCS (SD) 36.4 (9.9)
Unknown aetiology 482 (21%) Mean MCS (SD) 39.9 (13.0)
Other 148 (7%)
Mean duration of predialysis nephrologist
follow-up (months) (SD) (n = 2212)
36.8 (34.9) Haemodialysis technique (n = 2087)
≤6 months 610 (27%) Conventional 2047 (98%)
7–12 months 216 (10%) Specialg 40 (2%)
>12 months 1386 (63%) HD frequency, session/week (n = 2109)
Tobacco use (n = 2187) 3 session/week 2053 (97%)
Non-smoker 756 (35%) Other 56 (3%)
Former smoker 1181 (54%) Mean HD duration (hours/session) (SD) (n = 2091) 3.6 (0.7)
Current smoker 250 (11%) Membrane type (n = 2085)
Alcohol consumption (n = 2159) Low-flux 1158 (56%)
None 1908 (88%) High-flux 927 (44%)
Any 251 (12%) Heparin (n = 1695)
Employment status (n = 2151) Low molecular weight 804 (47%)
Retired 1328 (62%) Standard 891 (53%)
Disabled 308 (14%) Vascular access (n = 2124)
Active 271 (13%) Permanent catheter 347 (16%)
Unemployed 244 (11%) Temporary catheter 642 (30%)
Educational status (n = 2063) IAVF-distal 644 (31%)
Cannot read or write 138 (7%) IAVF-proximal 441 (21%)
Can read or write 643 (31%) PTFE graft 50 (2%)
Primary education 903 (44%) Blood pressure before HD session
Secondary education 266 (13%) Mean SBP (mmHg) (SD) (n = 1457) 140.5 (21.7)
University studies 113 (5%) Mean DBP (mmHg) (SD) (n = 1458) 75.4 (12.2)
Hepatitis B (+)( n = 2306) 25 (1%) Mean interdialysis weight gain (kg) (SD) (n = 1499) 1.07 (0.95)
Hepatitis C (+)( n = 2296) 119 (5%) Mean urea reduction ratio (%) (SD) (n = 1079) 62.3 (12.2)
HIV (+)( n = 2290) 16 (0.7%) Mean (eKt/V) (SD) (n = 1044) 1.17 (0.53)
Baseline demographic characteristics are described for 2341 incident haemodialysis patients recruited from 147 nephrology centres in Spain. Values
are expressed as number of patients and percentages on the valid sample indicated in parentheses for each variable.
N = number of patients; SD = standard deviation; p25 = percentile 25; p75 = percentile 75; WC = waist circumference; Abd. ob. = abdominal
obesity; IAVF = internal arteriovenous fistula; PTFE = polytetrafluoroethylene; SBP = systolic blood pressure; DBP = diastolic blood pressure;
CV = cardiovascular; HD = haemodialysis.
aPercentage calculated for the hypertensive, dyslipidaemic or diabetic patients with information available, respectively.
bExcluding left ventricular hypertrophy.
cCholesterol >220 mg/dl or LDL-C >100 mg/dl or treatment with statins.
dOn a scale 0–100, with 100 = the normal ability to carry out daily activities.
eAge adjusted; on a scale 0–37, with 37 = the highest comorbidity.
fSF-36 Physical Component Summary Scale (PCS) and Mental Component Summary Scale (MCS) are calculated based on T transformations, so that
the mean score of the general Spanish population is 50 and the standard deviation is 10 (a value between 45 and 55 is considered ‘normal’, between 40
and 45 ‘somewhat worse’ and <40 ‘worse’ than 70% of the general population).
gShort daily haemodialysis or nocturnal haemodialysis.ANSWER study: Spanish incident haemodialysis population 581
Comorbidities, functional status, medications and quality
of life
Comorbidities were common, particularly hypertension
(86%), with almost all hypertensive patients being
non-controlled (89% with SPB ≥140 mmHg or DBP
≥90 mmHg), despite most of them receiving antihyperten-
sive treatment (80%). There was also a high frequency of
previous cardiovascular disease (44%) and dyslipidaemia
(43%) (Table 1). The prevalence of diabetes mellitus was
10% higher than that of diabetic nephropathy. Approxi-
mately 1 in 10 patients had developed a tumour.
As expected, the use of concomitant medications reflects
the comorbidities in this population (Table 2). Half of the
patients were treated with iron supplements either before
(47%) or after (53%) the initiation of haemodialysis. Most
patients were receiving or were starting treatment with
erythropoiesis-stimulating agents (ESA, 80%) and phos-
phate binders (71%). Of the patients on ESAs, 52% were
treated prior to dialysis initiation (62% in the subgroup
with >6 months of predialysis nephrological care versus
38% in the ≤6 months group, P < 0.0001) and 48% began
ESA treatment at the time of dialysis initiation. The use of
beta-blockers was lower than expected in view of the co-
morbidities (24% of total sample, 16% as antihypertensive
treatment and 8% as cardiovascular therapy).
The presence of comorbidities [mean of Charlson Index
of 6.2 (SD 2.4)] resulted in a severely decreased quality of
life when compared with the general Spanish population
(Table 1). Over half of the patients (57%) had a Karnofsky
score between 80 and 100. Younger patients had a bet-
ter functional status [mean KS of 82 (SD 14) for patients
<65 years] than the older patients [71 (16) for patients
≥65 years, P < 0.0005].
Blood chemistry
Table 3 summarizes the patients’ baseline blood chemistry
values. A high proportion of diabetic patients had uncon-
trolled glycaemia (48% >126 mg/dl, 34% with HbA1c
>7%),whereasLDL-Cwasmostlywithinthenormalrange
and high-density lipoprotein (HDL)-cholesterol was below
the normal range in one-third of cases. The nutritional sta-
tus of the patients was quite poor (43% had albumin levels
<3.5 g/dl) and the inflammation status was highly variable
(SD 6.2 mg/dl for the C-reactive protein). The mean GFR
prior to dialysis onset was 7.6 (SD 2.8) ml/min/1.73 m2 and
the mean 24-h diuresis was 1602 (SD 920) ml.
Anaemia and mineral metabolism
A large proportion of patients were outside the EBPG tar-
gets for haematological parameters related to the manage-
ment of anaemia (haemoglobin <11 g/dl in 59%). Ferritin
and saturated transferrin levels were decreased in 31% and
39% of patients, respectively. Most patients were also out-
side the K/DOQI guideline target ranges for bone mineral
markers (Table 4). Overall, only 6.7% of the patients were
within the four K/DOQI target ranges at the same time. The
population means were also outside the K/DOQI guideline
target ranges for iPTH and phosphorus, but not for total
albumin-adjusted calcium or Ca × P, probably due to the
large percentage of patients with low total calcium levels.
Baseline haemodialysis characteristics
Baseline haemodialysis variables are detailed in Table 1.
The majority of patients received three haemodialysis ses-
sions per week with a mean of 3.6 h of dialysis per
session. Similar proportions of patients had high-flux or
low-flux membranes and similar proportions received low-
molecular-weight or standard heparin. Vascular access in
patients at the start of haemodialysis was achieved by using
either catheter (46%) or arteriovenous fistula (AVF) (52%)
and in a small proportion of patients using polytetrafluo-
roethylene AVF (2%).
Characteristics of the patients with initial vascular access
via a catheter
The patients with initial vascular access via a permanent
catheter were older and had worse nutritional status, more
comorbidities (higher Charlson index) and worse residual
renal function (lower 24-h diuresis) than patients with a
temporary catheter or an AVF (Table 5). The subgroup
with temporary catheters was characterized by greater
use of low-molecular-weight heparin and a higher de-
gree of anaemia, hypocalcaemia and hyperphosphataemia
(Table 5).
Characteristics of patients with late referral
to the nephrologist
In the subgroup analyses, patients who were referred to
the nephrologist <6 months before the start of dialysis had
worse functional and nutritional status, a lower degree of
dyslipidaemia and hypertension (and more recently diag-
nosed) and worse residual renal function (higher creatinine
and lower 24-h diuresis) than patients who referred >12
months ago (Table 6). As expected, systemic aetiologies
(e.g. myeloma and vasculitis) were also related to the late
referral to the nephrologist. Anaemia, hyperferritinaemia
and uncontrolled mineral metabolism (hypocalcaemia and
hyperphosphataemia)weremuchmorefrequentlyobserved
in the late referral group. Vascular access was obtained via
an AVF in only 25% of patients who were referred late
compared with 52–64% in the other subgroups.
Characteristics of patients with previous ischaemic
cardiovascular disease
The presence of previous ischaemic cardiovascular disease
in the incident dialysis population was related to all the
classic cardiovascular risk factors in the general popula-
tion (advanced age, male gender, former or current smoker,
diabetes mellitus, history of dyslipidaemia or hyperten-
sion) except obesity (Table 7). It is notable that despite
a higher percentage of dyslipidaemia and lower HDL-C
levels, the mean total cholesterol was lower in the pa-
tients with previous cardiovascular disease. This inverse
relationship was not due to the greater use of statins in582 R. P´ erez-Garc´ ıa et al.
Table 2. Use of concomitant medications at haemodialysis initiation
Valid NN (%) Valid NN (%)
Erythropoiesis-stimulating agentsa 2267 1814 (80%) Antihypertensives 2269 1815 (80%)
Rhu-Epo 1814 996 (54%) Calcium antagonists 1815 1101 (61%)
Darbepoetin alfa 1814 818 (45%) α-blockers 1815 563 (31%)
Ironb 2254 1127 (50%) ACE inhibitors 1815 554 (31%)
Intravenousc 1106 774 (70%) ARA II 1815 543 (30%)
Oralc 1106 332 (30%) β-blockers 1815 352 (19%)
Phosphate binders 2232 1585 (71%) Diuretics 1815 342 (19%)
CO3Ca 1585 1091 (69%) α /β-blockers 1815 130 (7%)
Sevelamer 1585 298 (19%) Other 1815 53 (3%)
Calcium acetate 1585 269 (17%) Cardiovascular drugs 2250 990 (44%)
Al(OH)3 1585 121 (8%) Nitrates 990 249 (25%)
Vitamin D analogues/metabolites 2216 687 (31%) β-blockers 990 184 (19%)
Calcitriol 687 666 (97%) Antiarrhythmic drugs 990 101 (10%)
Other 687 17 (2%) Digital 990 78 (8%)
Vitamins 2267 476 (21%) Other 990 378 (38%)
Folic acid 476 421 (88%) Antithrombotics 2259 655 (29%)
Vitamin C 476 198 (42%) Anticoagulants 2112 169 (8%)
Hypoglycaemics 2236 626 (28%) Hypolipidaemics 2228 713 (32%)
Insulin 626 540 (86%) Statins 713 676 (95%)
Oral antidiabetics 626 86 (14%) Fibrates 713 41 (6%)
Values are expressed as percentages on patients receiving the corresponding therapeutic group, except for major categories, calculated on total valid
sample. The valid N for each percentage is shown in the second and fifth columns. Total sample size, 2341.
N = number of patients; ACE = angiotensin-converting enzyme; ARAII = angiotensin II receptor antagonist.
aAmong patients on ESA, 52% were treated previously to HD initiation.
bAmong patients on iron, 47% were treated previously to HD initiation.
cPercentages calculated for the subgroup of patients receiving iron with information available.
Table 3. Blood chemistry at baseline
N Mean (SD) N patients (%)
Glucose (mg/dl) 2138 113 (46) ≥126 mg/dla 367 (48%)
HbA1c (%) 568 6.2 (1.5) >7%a 124 (34%)
Cholesterol (mg/dl) 1961 171 (46) >200 mg/dl 451 (23%)
Cholesterol HDL (mg/dl) 1269 47 (18) <40 mg/dl 457 (36%)
Cholesterol LDL (mg/dl) 1162 102 (37) >160 mg/dl 93 (8%)
Triglycerides (mg/dl) 1914 134 (70) >200 mg/dl 268 (14%)
Albumin (g/dl) 1796 3.5 (0.6) <3.5 g/dl 771 (43%)
3.5–4.0 g/dl 694 (39%)
>4.0 g/dl 331 (18%)
Creatinine (mg/dl) 2175 6.9 (2.5)
Serum urea (mg/dl) 2043 184 (69)
High-sensitivity C-reactive 313 5.3 (6.2)/3 (0.9, 7)b >7.5 mg/dl 72 (23%)
protein (mg/dl)
Vitamin B12 (pg/ml) 583 512 (204)
Lipoprotein A (mg/dl) 321 56 (47) >30 mg/dl 184 (58%)
Homocysteine (µmol/l) 361 25.9 (13) >18 µmol/l 253 (70%)
Fibrinogen (g/l) 533 5.3 (1.9) >4.5 g/l 331 (62%)
Potassium (mmol/l) 2177 4.9 (0.8)
Magnesium (mg/dl) 627 2.2 (0.5)
ALT (U/l) 1957 21 (40)
AST (U/l) 1929 20 (34)
Alkaline phosphatase (U/l) 1714 129 (92)
GFR (ml/min/1.73 m2) 1559 7.6 (2.8) <10 ml/min/1.73 m2 1294 (83%)
24-h diuresis (ml) 1370 1602 (920)
Percentages calculated on valid sample for each variable (indicated in the second column), unless otherwise specified.
N = sample size of the described variable; SD = standard deviation.
a% of diabetic patients with determination available (n = 765 for glucose, n = 360 for HbA1c).
bMedian (P25, P75).
the cardiovascular group (42% versus 58% in the non-
cardiovascular groups). Table 7 also shows greater catheter
use,worseresidualrenalfunctionandnutritionalstatus,and
a lower degree of hyperphosphataemia in this subgroup of
patients.
Discussion
ANSWER is the first large, prospective, observational
study of incident haemodialysis patients in Spain, which
will help to clarify, together with other recent ongoingANSWER study: Spanish incident haemodialysis population 583
Table 4. Haematological and bone mineral markers parameters at baseline
N Mean (SD) N patients (%)
<11 ≥11
Haemoglobin (g/dl) 2198 10.6 (1.7) 1289 (59%) 909 (41%)
<33 33–36 ≥37
Haematocrit (%) 2201 32.0 (5.2) 1244 (57%) 447 (20%) 510 (23%)
<100 100–500 >500
Ferritin (ng/ml) 1718 236 (238) 529 (31%) 1015 (59%) 174 (10%)
<20 20–40 41–100
Saturated transferrin (%) 1219 25.3 (13.8) 479 (39%) 611 (50%) 129 (11%)
Low Normala High
<150 150–300 >300
iPTH (pg/ml) 1556 348 (259) 425 (27%) 468 (30%) 663 (43%)
<3.5 3.5–5.5 >5.5
Phosphorus (mg/dl) 2109 5.6 (1.7) 129 (6%) 999 (47%) 981 (47%)
<8.4 8.4–9.5 >9.5
Adjusted calcium (mg/dl)b 1787 9.1 (1.0) 325 (18%) 846 (48%) 616 (34%)
na ≤55 >55
Ca × P (mg2/dl2) 1759 51 (15) na 1158 (66%) 601 (34%)
Percentages calculated on valid sample for each variable (indicated in the second column).
N = sample size; na = not applicable.
a‘Normal’ represents the K/DOQI guideline target range for bone mineral markers.
bAdjusted with the following formula: Adjusted Ca = calcium + 0.8 ∗(4-albumin).
Table 5. Differences in clinical and sociodemographic characteristics of incident haemodialysis patients grouped by the type of initial vascular access
(only those variables with significant differences with respect to AV fistula patients are displayed)
Permanent catheter
(N = 347, 16%)
Temporary catheter (N = 642,
30%)
AV fistulaa, reference
(N = 1085, 52%)
P-value∗
Age (years) 4.5 (2.3; 5.6) 1.1 (−0.4; 2.4) 0 <0.0001
Weight (kg) −4.4 (−5.8; −2.1) −2.22 (−3.4; −0.5) 0 0.0002
Karnofsky score −10 (−12; −7.9) −7( −8.5; −5.4) 0 <0.0001
Charlson index 1.2 (0.9; 1.4) 0.6 (0.3; 0.8) 0 <0.0001
CKD aetiology = diabetic
nephropathy
1.6 (1.2; 2.1) 1.5 (1.2; 1.9) 1 <0.0001
CKD aetiology =
glomerulonephritis
0.5 (0.3; 0.8) 0.7 (0.5; 1.0) 1 <0.0001
CKD aetiology = polycystic
kidney disease
0.3 (0.1; 0.5) 0.2 (0.1; 0.4) 1 <0.0001
CKD aetiology = systemic 3 (1.6; 5.5) 2.6 (1.5; 4.4) 1 <0.0001
Employment status = retired 1.4 (1.0; 1.8) 1 (0.8; 1.3) 1 0.0002
Haemodialysis duration
(hours/session)
0.1 (0.01; 0.18) 0.2 (0.13; 0.26) 1 <0.0001
Low-molecular-weight
heparin
0.8 (0.6; 1.1) 1.5 (1.2; 1.8) 1 <0.0001
Diabetes mellitus 1.6 (1.2; 2.0) 1.5 (1.2; 1.9) 1 <0.0001
Hypertension 0.4 (0.3; 0.6) 0.7 (0.5; 0.9) 1 <0.0001
Hypertension diagnosed <1
year beforeb
1.6 (0.9; 2.7) 2.3 (1.5; 3.4) 1 0.0002
Malnutrition 2.6 (1.8; 3.8) 1.6 (1.1; 2.2) 1 <0.0001
Albumin (g/dl) −0.4 (−0.47; −0.32) −0.4 (−0.44; −0.36.) 0 <0.0001
C-reactive protein (mg/dl) 0.3 (−2.2; 3.0) 3.3 (0.9; 5.8) 0 0.0001
Triglycerides (mg/dl) 21 (8; 35) 10 (0; 20) 0 <0.0001
Creatinine (mg/dl) 0.1 (−0.2; 0.4) 0.8 (0.5; 1.2) 0 <0.0001
Serum urea (mg/dl) −12 (−21.5; −2.4) 9 (1.6; 16.3) 0 <0.0001
24-h diuresis (ml) −474 (−285; −663) −342 (−181; 503) 0 <0.0001
Haemoglobin <11 g/dl 1.9 (1.5; 2.5) 2.6 (2.1; 3.2) 1 <0.0001
Ferritin ≥ 500 ng/ml 2 (1.3; 3.3) 2.7 (1.8; 4.0) 1 <0.0001
Ca <8.4 mg/dl 1.4 (0.9; 2.0) 1.8 (1.4; 2.4) 1 0.0002
PO4 >5.5 mg/dl 1.1 (0.9; 1.5) 1.4 (1.1; 1.7) 1 0.0001
Effect measures are expressed as a difference in means for quantitative variables and odds ratio for qualitative variables, together with their 95%
confidence interval, with respect to the reference subgroup (AV fistula as initial vascular access). For qualitative variables with more than one category,
the odds ratio has been calculated with respect to the absence of the displayed category.
N = sample size; CKD = chronic kidney disease.
∗Bonferroni-corrected significance limit: P < 0.00022 (0.05/228).
a2% patients with PTFE graft not included in the subgroup analysis.
bOnly analysed in the subgroup of hypertensive patients where the information was available, N = 1034.584 R. P´ erez-Garc´ ıa et al.
Table 6. Differencesinclinicalandsociodemographiccharacteristicsofincidenthaemodialysispatientsgroupedbydurationofpredialysisnephrological
care (only those variables with significant differences with respect to >12 months patients are displayed)
≤6 months
(N = 610, 27%)
7–12 months (N = 216,
10%)
>12 months, reference
(N = 1386, 63%)
P-value∗
Karnofsky scale −4.1 (−5.6; −2.3) −2.5 (−4.3; 0.3) 0 0.0001
BMI (kg/m2) −0.9 (−1.4; −0.3) −0.6 (−1.4; 0.2) 0 <0.0001
CKD aetiology = diabetic
nephropathy
0.8 (0.6; 1.0) 1.5 (1.1; 2.1) 1 <0.0001
CKD aetiology =
glomerulonephritis
0.6 (0.4; 0.9) 0.5 (0.2; 0.8) 1 0.0002
CKD aetiology = chronic
pyelonephritis
0.5 (0.3; 0.9) 0.9 (0.5; 1.7) 1 0.0002
CKD aetiology = polycystic
kidney disease
0.2 (0.1; 0.4) 0.2 (0; 0.5) 1 <0.0001
CKD aetiology = systemic 3.2 (2.0; 5.1) 1.4 (0.6; 3.2) 1 0.0002
Vascular access = IAVF 0.1 (0.1; 0.2) 0.6 (0.4; 0.8) 1 <0.0001
Diabetes diagnosed <1 year 15.7 (3.4; 72.4) 15.9 (3.1; 81.0) 1 <0.0001
beforea
Dyslipaemia 0.5 (0.4; 0.6) 0.7 (0.5; 1.0) 1 <0.0001
Dyslipidaemia diagnosed 12.3 (7.1; 21.3) 17.7 (8.7; 35.8) 1 <0.0001
<1 year beforeb
Hypertension 0.3 (0.2; 0.4) 0.5 (0.3; 0.7) 1 <0.0001
Hypertension diagnosed 16.4 (10.3; 26.0) 12 (6.8; 21.4) 1 <0.0001
<1 year beforec
Malnutrition 2 (1.5; 2.7) 1.3 (0.8; 2.1) 1 <0.0001
Albumin (g/dl) −0.3 (−0.37; −0.22) −0.1 (−0.21; 0.01) 0 <0.0001
Creatinine (mg/dl) 1.1 (0.8; 1.3) −0.3 (−0.61; 0.01) 0 <0.0001
24-h diuresis (ml) −378 (−492; −263.9) −142 (−306.3; 22.3) 0 <0.0001
Haemoglobin <11 g/dl 3.2 (2.5; 4.0) 0.9 (0.7; 1.2) 1 <0.0001
Ferritin ≥500 ng/ml 2.7 (1.9; 3.8) 1.2 (0.6; 2.1) 1 <0.0001
Ca <8.4 mg/dl 1.9 (1.4; 2.5) 0.8 (0.5; 1.3) 1 <0.0001
PO4 >5.5 mg/dl 1.6 (1.3; 1.9) 0.8 (0.6; 1.1) 1 <0.0001
Effect measures are expressed as a difference in means for quantitative variables and odds ratio for qualitative variables, together with their 95%
confidence interval, with respect to the reference subgroup (predialysis nephrological care >12 months). For qualitative variables with more than one
category, the odds ratio has been calculated with respect to the absence of the displayed category.
N = sample size; CKD = chronic kidney disease.
∗Bonferroni-corrected significance limit: P < 0.00022 (0.05/228).
aOnly analysed in the subgroup of diabetic patients where the information was available, N = 460.
bOnly analysed in the subgroup of dyslipidaemic patients where the information was available, N = 512.
cOnly analysed in the subgroup of hypertensive patients where the information was available, N = 1156.
studies in Europe (the Netherlands [7,8], France [10–
12], Italy [13,14] and Sweden [15]) and North America
(CHOICE [29], Wave-2 USRDS [30–32]), the risk factors
associated with cardiovascular morbidity and mortality in
these patients. The ANSWER study enrolled all consec-
utive incident haemodialysis patients, whereas most other
haemodialysis studies have excluded patients who did not
survive the first 3 months [7,14,29,31] or have included
‘prevalent’ patients (DOPPS [33], MAR [34]). Studies of
‘incident’ populations are needed to verify the previously
described associations for ‘prevalent’ populations, because
thosestudiessufferedfromthebiasofnotenrollingpatients
with higher cardiovascular risk, that is, those who die in the
first months after dialysis onset.
The sociodemographic characteristics of our cohort are
similar to those reported for other European incident popu-
lations. The mean age and percentage of patients older than
65 or 75 years in our sample are similar to those reported
in other European countries [8–10,14]) and the USA [35].
About a quarter of the patients developed renal failure
due to diabetic nephropathy. This figure is similar to that
reported in other European studies [12,13,16,36–38]. The
prevalence of vascular nephropathy in the present study is
also similar to that reported in other Spanish and Italian
studies [13,16], but it seems slightly lower than the preva-
lencereportedfromtheNetherlands[8]orFrance[9,10,12].
Our resultssupport the findings of L´ opez Revuelta and col-
leagues [16] that the aetiology of chronic kidney disease in
European incident haemodialysis populations is different
from the aetiology among the incident population in the
USA, where diabetes and hypertension account for >70%
of cases, compared with <50% in Europe.
Duetothehighmeanageofthestudypopulationandsig-
nificant prevalence of comorbidities, the functional status
was moderately affected, consistent with findings of previ-
ous Spanish studies in the incident haemodialysis popula-
tion [38]. Interestingly, the functional status in our patients
is better than that of incident patients in the UK of sim-
ilar mean age [39,40], but is similar to that of American
patients, who were an average of 10 years younger [41].
The gender distribution in both the UK and US samples
was different from ours (more males in the UK and US
samples), but the worse functional status of the UK sample
may be related to the higher proportion of unplanned initia-
tion of haemodialysis in that population (44–47%) [39,40].
The QoL results revealed severely affected physical andANSWER study: Spanish incident haemodialysis population 585
Table 7. Differences in clinical and sociodemographic characteristics of incident haemodialysis patients grouped by the presence of previous ischaemic
cardiovascular disease (only those variables with significant differences are displayed)
With previous ischaemic
CVD (N = 1640, 70%)
Without previous ischaemic
CVD, reference (N = 701,
30%)
P-value∗
Age (years) 7.3 (5.9; 8) 0 <0.0001
Karnofsky score −7.4 (−8.4; −5.5) 0 <0.0001
Charlson index 2.3 (2.1; 2.4) 0 <0.0001
Male gender 2 (1.6; 2.5) 1 <0.0001
CKD aetiology = diabetic
nephropathy
2.5 (2.0; 3.0) 1 <0.0001
CKD aetiology = vascular
nephropathy
2.4 (1.9; 3.0) 1 <0.0001
Former smoker 1.8 (1.4; 2.3) 1 <0.0001
Current smoker 1.7 (1.2; 2.3) 1 <0.0001
Employment status = retired 2.5 (2.0; 3.1) 1 <0.0001
Vascular access = IAVF 0.6 (0.5; 0.7) 1 <0.0001
Diabetes mellitus 2.7 (2.2; 3.2) 1 <0.0001
Dyslipidaemia 2.3 (1.0; 2.7) 1 <0.0001
Hypertension 2.7 (1.9; 3.7) 1 <0.0001
Hypertension diagnosed >5 2.1 (1.6; 2.8) 1 <0.0001
years beforea
HbA1c (%) 0.5 (0.2; 0.7) 0 0.0002
Albumin (g/dl) −0.1 (−0.16; −0.03) 0 0.0002
Cholesterol (mg/dl) −8( −12.3; −3.6) 0 <0.0001
HDL-cholesterol (mg/dl) −4.5 (−7.2; −1.7) 0 <0.0001
Creatinine (mg/dl) −0.8 (−1; −0.5) 0 <0.0001
24-h diuresis (ml) −185 (−285; −84.9) 0 <0.0001
PO4 > 5.5 mg/dl 0.7 (0.6; 0.8) 1 0.0002
Effect measures are expressed as a difference in means for quantitative variables and odds ratio for qualitative variables, together with their 95%
confidence interval, with respect to the reference subgroup (non-previous ischaemic cardiovascular disease). For qualitative variables with moret h a n
one category, the odds ratio has been calculated with respect to the absence of the displayed category.
N = sample size; CKD = chronic kidney disease; CVD = cardiovascular disease.
∗Bonferroni-corrected significance limit: P < 0.00022 (0.05/228).
aOnly analysed in the subgroup of hypertensive patients where the information was available, N = 1174.
mental health, similar to previous reports of Spanish inci-
dent haemodialysis patients [42,43].
Regarding the use of catheter as first vascular access,
we found fewer shunts than reported in the DOPPS study
for Spain. This may be attributed to the differences among
recruiting facilities [44,45]. The fact that there are many
more facilities participating in the ANSWER study (147
compared with 20 in the DOPPS) probably provides a more
confident estimate of the real situation of vascular access
in Spain. Furthermore, our results are in agreement with
previous studies in Spain, in which between 46% and 51%
of incident patients were found not to have permanent AVF
access[46,47],andthisproportionhasremainedstabledur-
ing the past few years [48].
Although a minimum nephrological follow-up of
6 months prior to haemodialysis onset is recommended,
late referral has been reported for about a quarter of Span-
ish incident patients, similar to previous findings from
other European countries [9,49,50]. The high proportion
of catheter use in the late referral group, also described in
DOPPS [51], highlights the need for early referral as far
as possible. A shorter time of nephrologist follow-up has
been associated with higher mortality in haemodialysis pa-
tients independent of catheter vascular access [52], indicat-
ing the presence of other negative factors in these patients.
Theworseclinicalstatusattheonsetofhaemodialysisinthe
late referral subgroup may contribute to this phenomenon
[53,54].
With respect to kidney function at haemodialysis onset
in our patients, the GFR was lower in our patients com-
pared with reports from previous studies in Spain and other
European countries [49,50,55], and 8 in 10 patients were
below the limitof 10 ml/min recommended by the K/DOQI
guidelines [56]. These data suggest a delayed onset of
haemodialysis in our settings. Initiation of haemodialy-
sis above this limit may prolong survival according to the
NECOSAD study [57]. Other haemodialysis quality indi-
cators,suchasthelowinitialeKt/V,alsosuggestinadequate
haemodialysis onset although almost half the patients are
using high-flux membranes.
About 10% of the population had history of neoplasia.
This figure is a bit higher than that reported for the Span-
ish DOPPS cohort (6%), but agrees with the 9% of the
EURO-DOPPS [36] prevalent patients and also with the
11% reported for the incident French population [10] (al-
though that study considered only active neoplasia).
The antecedents of cardiovascular disease in our sam-
ple were, as expected, very common. The prevalence of
ischaemic heart disease was similar to that in Italy, France
and Sweden [11,14,15,58], but lower than that in the UK,
Germany and the USA [58,35]. The prevalence of periph-
eral vascular disease was similar to that in Sweden and586 R. P´ erez-Garc´ ıa et al.
the USA [14,35], but lower than the prevalence in France,
Germany, Italy and the UK [9,11,58]. The prevalence of
heart failure was similar to that in France, Germany and
Italy [9,58], but lower than the prevalence in the UK and
the USA [58,35]. Finally, the prevalence of cerebrovascular
disease was a little higher than or similar to that in Italy,
France, Sweden and the USA [9,11,13,15,35]. The differ-
ences in these prevalences must be viewed with caution,
as they may be related to different disease definitions or
methods of collection.
With regard to the prevalence of classic cardiovascu-
lar risk factors, the majority of patients had uncontrolled
hypertension, despite almost all patients receiving antihy-
pertensive treatment. Diabetes affected one-third of our
patients, similar to other European studies [12,15], and
far from one-half in the USA [59,35]. Glycaemic control
was poor, and 1 in 5 patients were obese. Both the pro-
portion of obese patients and the mean BMI were highly
consistent with the findings from almost all previously de-
scribedincidentEuropeanandNorthAmericanpopulations
[7,15,32,35,50,59]. However, malnutrition was less preva-
lentinoursamplethanintheNetherlandsorSweden[7,15].
This discordance is probably due to an underestimation
of malnutrition by Spanish physicians, as one-third of our
patients had low albumin levels. The high prevalence of
other emergent cardiovascular risk factors (hyperhomocys-
teinaemia, hyperfibrinogenaemia and elevated lipoprotein
(a))inoursamplewithrespecttothegeneralSpanishpopu-
lation[60]agreeswithpreviousresultsinmaintenance [61]
and incident [10] haemodialysis patients. Since this is a
cross-sectional analysis, the causal relationship between all
these findings and cardiovascular status cannot be verified.
Future data will produce more reliable results regarding the
predictive value of the collected variables.
Anaemia-related target ranges, which are strongly pre-
dictive of reduced mortality in chronic kidney disease
[2,6], were achieved by a relatively low percentage of pa-
tients. Despite almost 1 in 2 patients receiving ESAs prior
to haemodialysis onset, >50% were anaemic, and more
than one-third had iron deficiency, which suggests incor-
rect ESA administration and insufficient correction of iron
stores. Less than 1 in 10 patients were within the K/DOQI
targets for all four bone and mineral metabolism param-
eters, iPTH being the most uncontrolled. These findings
correlate with those from the NECOSAD study [7]. Data
from prevalent populations indicate that the degree of con-
trol of bone mineral disease is not better after the onset of
haemodialysis [62]. Studies of the recently available thera-
pies(calcimimetics,calcium-freeP-chelatingagentsornew
vitamin D analogues) may help to resolve this issue in the
near future.
With regard to the classic cardiovascular risk factors,
the expected associations with previous smoking, dyslip-
idaemia, hypertension and diabetes were observed in pa-
tients with a history of cardiovascular disease. However,
the cholesterol levels were lower in the group with car-
diovascular disease, which could be related to the worse
nutritional status in those patients.
This cohort study has some limitations. The non-random
(but consecutive) patient selection may have resulted in
someselectionbias.However,theextendedinclusionperiod
and the fact that the final sample represents more than half
of all incident Spanish patients during this period [27,28]
support the validity of the recruited cohort. In addition, as
enrolment at each site was stratified according to the inci-
dence of haemodialysis in a reference population, the 2341
patients in the study were considered to be representative
of the target population in Spain.
For the purposes of international comparisons, our study
confirms that there are important differences in the preva-
lenceofcardiovascularandmortalityriskfactors,especially
with respect to North American populations. Spain has an
extremely high rate of renal transplantation (47% of pa-
tients on renal replacement therapy in 2004 [28] versus
29% in the USA [63]). This should be taken into account
when comparing the prospective cardiovascular morbidity
and mortality results in the future.
In summary, the ANSWER study provides valuable new
data, thus adding to our knowledge of the characteristics of
incident haemodialysis patients in Spain and Europe. Most
patients present at an advanced age and have hypertension,
diabetes and previous cardiovascular disease. Their func-
tional status is moderately affected, considering the high
mean age. Our results also show that in the Spanish setting,
haemodialysis is started too late and that patients are also
referred too late to the nephrologist (late referral for 1 in
4 patients with diabetic and vascular nephropathy). Also,
not enough effort was made to place a permanent AVF be-
fore haemodialysis onset in patients referred >6 months
ago, and such efforts must be specially made in older and
diabetic patients.
Thisstudyhasalsorevealedanextremelyhighprevalence
of emergent and uraemia-related cardiovascular risk fac-
torsandpoorglycaemiccontrol,lowHDL-C,hypertension,
anaemia, malnutrition, hypo- and hyperparathyroidism, hy-
perphosphataemia and hypo- and hypercalcaemia. These
results reflect the need for improving the therapeutic man-
agement of incident dialysis patients before the onset of
haemodialysis.
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